Entrada Therapeutics Forecast, price target & analysts
Entrada Therapeutics Target price 2026 - Analyst rating & recommendation
Entrada Therapeutics Classifications & Recommendation
Entrada Therapeutics Price Target
| Target Price | $17.34 |
| Price | $6.89 |
| Potential |
151.67%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Entrada Therapeutics 2027 .
The average Entrada Therapeutics target price is $17.34.
This is
151.67%
register free of charge
$26.25
280.99%
register free of charge
$7.31
6.13%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend Entrada Therapeutics to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Entrada Therapeutics stock has an average upside potential 2027 of
151.67%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 25.42 | 17.23 |
| 87.94% | 32.21% | |
| EBITDA Margin | -605.04% | -948.55% |
| 2,611.41% | 56.78% | |
| Net Margin | -565.50% | -894.84% |
| 1,916.18% | 58.24% |
10 Analysts have issued a sales forecast Entrada Therapeutics 2026 . The average Entrada Therapeutics sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Entrada Therapeutics EBITDA forecast 2026. The average Entrada Therapeutics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Entrada Therapeutics Analysts have issued a net profit forecast 2026. The average Entrada Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.47 | -3.96 |
| 306.55% | 14.12% | |
| P/E | negative | |
| EV/Sales | 2.63 |
10 Analysts have issued a Entrada Therapeutics forecast for earnings per share. The average Entrada Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
Entrada Therapeutics...
Current Entrada Therapeutics Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim |
Locked
➜
Locked
|
Locked | Jun 08 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 08 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Apr 06 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 18 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Feb 11 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 20 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jun 08 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 08 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Apr 06 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 18 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Feb 11 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 20 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 31 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
